For example, coinhibition of LSD1 and BRD4 (BETi), or LSD1 and JAK2 (ruxolitinib), shows synergistic efficacy in AML and secondary AML post-MPN by disrupting enhancer regulation and overcoming nongenetic resistance mechanisms (64). Here, KDM1A is linked to myeloproliferative neoplasm.